Page 2 - Treatment Optimization News Today

MEDIA & INVESTOR RELEASE Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard-of-care TKIs in Phase III trial for...

Experts discuss the critical role of specialty pharmacists in advocating for patients during challenging moments in their hemophilia treatment journey and explore precision dosing considerations and the importance of adherence to dosing guidelines.

Heather McArthur, MD, and Debu Tripathy, MD, lead a discussion on risk stratification and optimizing treatment for HER2+ early breast cancer (eBC), followed by a review of standard-of-care systemic therapy regimens in the preoperative/neoadjuvant setting.

AI and machine learning algorithms will revolutionize healthcare, improving diagnostics, personalized medicine, and drug discovery.

Society for Science proudly announces the top 300 scholars in the Regeneron Science Talent Search 2021, the nation’s oldest and most prestigious science and math competition for high school seniors.

The reuse of produced water is on the rise as water management evolves in the U.S. shale industry.

Novartis Scemblix®, with novel mechanism of action, approved by the European Commission for adult patients with chronic myeloid leukemia

While AI offers benefits, there are potential negative effects dental professionals should be aware of cautions a Journal of Dental Sciences commentary.

With unique STAMP mechanism of action, Scemblix could provide a new option for patients in Europe with chronic myeloid leukemia (CML) who have suffered intolerance or inadequate response with at least

Scemblix® (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif®* (bosutinib) at 96...